Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Innocenti, F.
Right arrow Articles by Ratain, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Innocenti, F.
Right arrow Articles by Ratain, M. J.
Clinical Cancer Research Vol. 6, 3400-3405, September 2000
© 2000 American Association for Cancer Research

Advances in Brief

Flavopiridol Metabolism in Cancer Patients Is Associated with the Occurrence of Diarrhea1

Federico Innocenti, Walter M. Stadler, Lalitha Iyer, Jacqueline Ramírez, Everett E. Vokes and Mark J. Ratain2

Department of Medicine [F. I., W. M. S., L. I., J. R., E. E. V., M. J. R.], Cancer Research Center [W. M. S., E. E. V., M. J. R.], Committee on Cancer Biology, [W. M. S.], and Committee on Clinical Pharmacology [L. I., M. J. R.], University of Chicago, Chicago, Illinois 60637

Flavopiridol, a cyclin-dependent kinase inhibitor currently undergoing clinical evaluation, has a dose-limiting toxicity of diarrhea. Preclinical data on flavopiridol metabolism indicate that flavopiridol undergoes hepatic glucuronidation. The purpose of this study is to evaluate whether the occurrence of diarrhea is related to the systemic glucuronidation of flavopiridol. Parent drug and metabolite concentrations in plasma were measured by high-pressure liquid chromatography in 22 metastatic renal cancer patients treated on a Phase II trial of 50 mg/m2/day of flavopiridol administered every 2 weeks as a 72-h continuous infusion. Pharmacokinetics of flavopiridol and its glucuronide were assessed during the first cycle at 23, 47, and 71 h during the infusion. Flavopiridol concentrations at 23, 47, and 71 h were 389 nM (296–567 nM), 412 nM (297–566 nM), and 397 nM (303–597 nM) [median (interquartile range)], respectively. Flavopiridol glucuronide reached a plateau of 358 nM (196–553 nM) at 47 h. Metabolic ratios of flavopiridol glucuronide:flavopiridol at 71 h showed an apparent bimodal distribution with an antimode of 1.2. Thirteen patients experienced diarrhea and had lower metabolic ratios [0.72 (0.53–0.86)] than patients without diarrhea [2.24 (1.76–2.3); P = 0.002]. Eight of 11 extensive glucuronidators (ratio > 1.2) did not develop diarrhea, whereas 10 of 11 poor glucuronidators (ratio < 1.2) developed diarrhea (P = 0.008). The glucuronidation of flavopiridol is apparently polymorphic, suggesting a genetic etiology. The systemic glucuronidation of flavopiridol is inversely associated with the risk of developing diarrhea.




This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
J. Ramirez, W. Liu, S. Mirkov, A. A. Desai, P. Chen, S. Das, F. Innocenti, and M. J. Ratain
Lack of Association between Common Polymorphisms in UGT1A9 and Gene Expression and Activity
Drug Metab. Dispos., December 1, 2007; 35(12): 2149 - 2153.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Whitlock, M. Krailo, J. M. Reid, S. L. Ruben, M. M. Ames, W. Owen, and G. Reaman
Phase I Clinical and Pharmacokinetic Study of Flavopiridol in Children With Refractory Solid Tumors: A Children's Oncology Group Study
J. Clin. Oncol., December 20, 2005; 23(36): 9179 - 9186.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. C. Bible, J. L. Lensing, S. A. Nelson, Y. K. Lee, J. M. Reid, M. M. Ames, C. R. Isham, J. Piens, S. L. Rubin, J. Rubin, et al.
Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points
Clin. Cancer Res., August 15, 2005; 11(16): 5935 - 5941.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. R. Brown
Chronic Lymphocytic Leukemia: A Niche for Flavopiridol?
Clin. Cancer Res., June 1, 2005; 11(11): 3971 - 3973.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. C. Byrd, B. L. Peterson, J. Gabrilove, O. M. Odenike, M. R. Grever, K. Rai, R. A. Larson, and the Cancer and Leukemia Group B
Treatment of Relapsed Chronic Lymphocytic Leukemia by 72-Hour Continuous Infusion or 1-Hour Bolus Infusion of Flavopiridol: Results from Cancer and Leukemia Group B Study 19805
Clin. Cancer Res., June 1, 2005; 11(11): 4176 - 4181.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Liu, D. R. Gandara, P. N. Lara Jr., D. Raghavan, J. H. Doroshow, P. Twardowski, P. Kantoff, W. Oh, K. Kim, and G. Wilding
A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer
Clin. Cancer Res., February 1, 2004; 10(3): 924 - 928.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. A Rudek, K. S Bauer Jr, R. M Lush III, S. F Stinson, A. M Senderowicz, D. J Headlee, S. G Arbuck, M. C Cox, A. J Murgo, E. A Sausville, et al.
Clinical Pharmacology of Flavopiridol Following a 72-Hour Continuous Infusion
Ann. Pharmacother., October 1, 2003; 37(10): 1369 - 1374.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
U. Raju, E. Nakata, K. A. Mason, K. K. Ang, and L. Milas
Flavopiridol, a Cyclin-dependent Kinase Inhibitor, Enhances Radiosensitivity of Ovarian Carcinoma Cells
Cancer Res., June 15, 2003; 63(12): 3263 - 3267.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
L. M. Schang
Cyclin-dependent kinases as cellular targets for antiviral drugs
J. Antimicrob. Chemother., December 1, 2002; 50(6): 779 - 792.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. R. Tan, D. Headlee, R. Messmann, E. A. Sausville, S. G. Arbuck, A. J. Murgo, G. Melillo, S. Zhai, W. D. Figg, S. M. Swain, et al.
Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms
J. Clin. Oncol., October 1, 2002; 20(19): 4074 - 4082.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Raymond, W.W. ten Bokkel Huinink, J. Taieb, J.H. Beijnen, S. Faivre, J. Wanders, M. Ravic, P. Fumoleau, J.P. Armand, and J.H.M. Schellens
Phase I and Pharmacokinetic Study of E7070, a Novel Chloroindolyl Sulfonamide Cell-Cycle Inhibitor, Administered as a One-Hour Infusion Every Three Weeks in Patients With Advanced Cancer
J. Clin. Oncol., August 15, 2002; 20(16): 3508 - 3521.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. M. Senderowicz
The Cell Cycle as a Target for Cancer Therapy: Basic and Clinical Findings with the Small Molecule Inhibitors Flavopiridol and UCN-01
Oncologist, August 1, 2002; 7(90003): 12 - 19.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
L. M. Schang, A. Bantly, M. Knockaert, F. Shaheen, L. Meijer, M. H. Malim, N. S. Gray, and P. A. Schaffer
Pharmacological Cyclin-Dependent Kinase Inhibitors Inhibit Replication of Wild-Type and Drug-Resistant Strains of Herpes Simplex Virus and Human Immunodeficiency Virus Type 1 by Targeting Cellular, Not Viral, Proteins
J. Virol., June 27, 2002; 76(15): 7874 - 7882.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. K. Schwartz, E. O'Reilly, D. Ilson, L. Saltz, S. Sharma, W. Tong, P. Maslak, M. Stoltz, L. Eden, P. Perkins, et al.
Phase I Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination With Paclitaxel in Patients With Advanced Solid Tumors
J. Clin. Oncol., April 15, 2002; 20(8): 2157 - 2170.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
Y. A. Elsayed and E. A. Sausville
Selected Novel Anticancer Treatments Targeting Cell Signaling Proteins
Oncologist, December 1, 2001; 6(6): 517 - 537.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. I. Shapiro, J. G. Supko, A. Patterson, C. Lynch, J. Lucca, P. F. Zacarola, A. Muzikansky, J. J. Wright, T. J. Lynch Jr., and B. J. Rollins
A Phase II Trial of the Cyclin-dependent Kinase Inhibitor Flavopiridol in Patients with Previously Untreated Stage IV Non-Small Cell Lung Cancer
Clin. Cancer Res., June 1, 2001; 7(6): 1590 - 1599.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
F. Innocenti, L. Iyer, J. Ramírez, M. D. Green, and M. J. Ratain
Epirubicin Glucuronidation Is Catalyzed by Human UDP-Glucuronosyltransferase 2B7
Drug Metab. Dispos., April 13, 2001; 29(5): 686 - 692.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
B. Hagenauer, A. Salamon, T. Thalhammer, O. Kunert, E. Haslinger, P. Klingler, A. M. Senderowicz, E. A. Sausville, and W. Jäger
In Vitro Glucuronidation of the Cyclin-Dependent Kinase Inhibitor Flavopiridol by Rat and Human Liver Microsomes: Involvement of UDP-Glucuronosyltransferases 1A1 and 1A9
Drug Metab. Dispos., April 1, 2001; 29(4): 407 - 414.
[Abstract] [Full Text]

Home page
 ASH Education BookHome page
R. J. Klasa, A. F. List, and B. D. Cheson
Rational Approaches to Design of Therapeutics Targeting Molecular Markers
Hematology, January 1, 2001; 2001(1): 443 - 462.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.